Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium

VM. Cnossen, PCL. Moreira, OG. Engelhardt, J. Samolej, GH. Groeneveld, SP. Jochems, W. Huisman, GK. Pedersen, K. Wørzner, L. Recek, G. Piccini, CM. Trombetta, A. Aspelund, A. Hoag, M. Reiter, C. Wick, T. Muster, IMC. Kamerling

. 2025 ; 16 (-) : 1568778. [pub] 20250523

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015673

Influenza is a significant global health problem, causing disease and hospitalisations in elderly individuals and infants. While updated vaccines are available every year, their effectiveness is moderate at best. FLUniversal is a European Union funded consortium, aiming to develop a universal influenza vaccine by bringing together partners with expertise in different areas of vaccine development. An intranasal live attenuated vaccine, DeltaFLU, will be produced using an innovative platform; preclinical assessment in animal models and clinical studies using a controlled human infection model (CHIM) will be conducted for assessment of safety, immunogenicity and protective efficacy; and finally, comprehensive immunological analysis of blood and nasal mucosa will elucidate vaccine responses and potential new correlates of protection (CoPs). In addition to a universal influenza vaccine, listed as a top priority by the EU, FLUniversal seeks to deliver an enhanced vaccine manufacturing technology that is superior in terms of efficiency, production costs and production speed - especially critical in the face of a potential new pandemic. Moreover, an influenza CHIM with a focus on harmonisation of clinical procedures and assays will be established to generate translatable and reproducible data. Newly generated knowledge on mechanisms of protection, CoPs and new molecular analysis tools may significantly contribute to our knowledge on influenza infection and influenza vaccines. In conclusion, FLUniversal is an innovative and ambitious public-private partnership, aiming to present a new development pathway for influenza vaccines, and maximising impact by bringing together leading partners from academy and industry with a shared purpose of collaboration and innovation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015673
003      
CZ-PrNML
005      
20250731091149.0
007      
ta
008      
250708e20250523sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2025.1568778 $2 doi
035    __
$a (PubMed)40486504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Cnossen, Victor M $u Centre for Human Drug Research, Leiden, Netherlands
245    10
$a Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium / $c VM. Cnossen, PCL. Moreira, OG. Engelhardt, J. Samolej, GH. Groeneveld, SP. Jochems, W. Huisman, GK. Pedersen, K. Wørzner, L. Recek, G. Piccini, CM. Trombetta, A. Aspelund, A. Hoag, M. Reiter, C. Wick, T. Muster, IMC. Kamerling
520    9_
$a Influenza is a significant global health problem, causing disease and hospitalisations in elderly individuals and infants. While updated vaccines are available every year, their effectiveness is moderate at best. FLUniversal is a European Union funded consortium, aiming to develop a universal influenza vaccine by bringing together partners with expertise in different areas of vaccine development. An intranasal live attenuated vaccine, DeltaFLU, will be produced using an innovative platform; preclinical assessment in animal models and clinical studies using a controlled human infection model (CHIM) will be conducted for assessment of safety, immunogenicity and protective efficacy; and finally, comprehensive immunological analysis of blood and nasal mucosa will elucidate vaccine responses and potential new correlates of protection (CoPs). In addition to a universal influenza vaccine, listed as a top priority by the EU, FLUniversal seeks to deliver an enhanced vaccine manufacturing technology that is superior in terms of efficiency, production costs and production speed - especially critical in the face of a potential new pandemic. Moreover, an influenza CHIM with a focus on harmonisation of clinical procedures and assays will be established to generate translatable and reproducible data. Newly generated knowledge on mechanisms of protection, CoPs and new molecular analysis tools may significantly contribute to our knowledge on influenza infection and influenza vaccines. In conclusion, FLUniversal is an innovative and ambitious public-private partnership, aiming to present a new development pathway for influenza vaccines, and maximising impact by bringing together leading partners from academy and industry with a shared purpose of collaboration and innovation.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a aplikace intranazální $7 D000281
650    _2
$a Evropská unie $7 D005062
650    12
$a vakcíny proti chřipce $x imunologie $x aplikace a dávkování $7 D007252
650    12
$a chřipka lidská $x prevence a kontrola $x imunologie $7 D007251
650    12
$a partnerství veřejného a soukromého sektoru $7 D055818
650    12
$a vývoj vakcíny $7 D000087506
650    _2
$a atenuované vakcíny $x imunologie $x aplikace a dávkování $7 D014613
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moreira, Paula C Leao $u Centre for Human Drug Research, Leiden, Netherlands
700    1_
$a Engelhardt, Othmar G $u Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
700    1_
$a Samolej, Jerzy $u Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
700    1_
$a Groeneveld, Geert H $u Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands $u Department of Internal Medicine - Acute Internal Medicine, Leiden University Medical Center, Leiden, Netherlands
700    1_
$a Jochems, Simon P $u Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands
700    1_
$a Huisman, Wesley $u Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands
700    1_
$a Pedersen, Gabriel K $u Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Wørzner, Katharina $u Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Recek, Lukas $u MediTox S.R.O., Konárovice, Czechia
700    1_
$a Piccini, Giulia $u VisMederi S.r.l., Siena, Italy
700    1_
$a Trombetta, Claudia M $u VisMederi S.r.l., Siena, Italy $u Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
700    1_
$a Aspelund, Amy $u Vivaldi Biosciences, Vienna, Austria
700    1_
$a Hoag, Alaura $u Vivaldi Biosciences, Vienna, Austria
700    1_
$a Reiter, Manfred $u Vivaldi Biosciences, Vienna, Austria
700    1_
$a Wick, Carrie $u Vivaldi Biosciences, Vienna, Austria
700    1_
$a Muster, Thomas $u Vivaldi Biosciences, Vienna, Austria
700    1_
$a Kamerling, Ingrid Maria Catharina $u Centre for Human Drug Research, Leiden, Netherlands $u Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 16 (20250523), s. 1568778
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40486504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091143 $b ABA008
999    __
$a ok $b bmc $g 2366496 $s 1252798
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1568778 $e 20250523 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace